The Scientific Leadership Board (SLB) provides recommendations for leadership and staff to guide program and project development in support of the organization’s mission. The SLB works primarily on clinical and translational research and excellence in clinical care but also advises on public policy, patient services, and other areas of the organization, as needed.
The SLB includes four committees dedicated to increasing rates of early detection, advancing comprehensive biomarker testing and precision medicine, increasing reach and impact of community engagement, and improving quality of life. Each of these committees reflects one of GO2 for Lung Cancer’s four strategic priorities aimed at doubling the five-year survival rate from 20% to 40% by 2025.
Chair, Scientific Leadership Board
Christine M. Lovly, MD, PhD, Associate Professor of Medicine, Vanderbilt University Medical Center
Vice Chair, Scientific Leadership Board
William R. Mayfield, MD, FACS, Thoracic Surgeon, Chief Surgical Officer, WellStar Health System
Early Detection Committee
- Debra S. Dyer, MD, FACR, Professor and Chair, Department of Radiology, National Jewish Health
- William R. Mayfield, MD, FACS, Thoracic Surgeon; Chief Surgical Officer, WellStar Health System
- Peter Mazzone, MD, MPH, FCCP, Director, Lung Cancer Program, Respiratory Institute, Cleveland Clinic
- Jacob Sands, MD, Physician, Instructor, Dana-Farber Cancer Institute, Harvard Medical School
- Douglas E. Wood, MD, FACS, FRCSEd, The Henry N. Harkins Professor and Chair, Department of Surgery, University of Washington
Biomarker Testing and Precision Medicine Committee
- Trever Bivona, MD, PhD, Professor, University of California, San Francisco
- Hossein Borghaei, DO, MS, Professor and Chief, Thoracic Oncology, Fox Chase Cancer Center
- Karen Kelly, MD, Professor of Medicine, Associate Director for Clinical Research, University of California, Davis Comprehensive Cancer Center
- Christine Lovly, MD, PhD, Associate Professor of Medicine (Hematology/Oncology), Ingram Associate Professor of Cancer Research, and Co-Leader, Translational Research and Interventional Oncology Research Program; Vanderbilt University Medical Center
- Kathryn F. Mileham, MD, FACP, Chief, Section of Thoracic Oncology, Atrium Health – Levine Cancer Institute
- Luis E. Raez, MD, FACP, FCCP, Medical Director & Chief Scientific Officer;; Memorial Cancer Institute, Memorial Health Care System; Clinical Professor of Medicine; Herbert Wertheim College of Medicine, Florida International University
- Natasha Rekhtman, MD, PhD, Attending Pathologist, Thoracic Pathology & Cytopathology, Memorial Sloan Kettering Cancer Center
Community Engagement Committee
- Jan M. Eberth, PhD, FACE, Associate Professor of Epidemiology and Director, Rural and Minority Health Research Center, University of South Carolina Arnold School of Public Health
- Jhanelle E. Gray, MD, Department Chair, Program Leader & Senior Member, Thoracic Oncology; Co-Leader Molecular Medicine Program, Moffitt Cancer Center
- Drew Moghanaki, MD, MPH, Professor of Radiation Oncology, David Geffen School of Medicine at UCLA , Chief of Thoracic Oncology Section; UCLA Department of Radiation Oncology; Staff Physician, Veterans Affairs Greater Los Angeles Healthcare System
- Jamie S. Ostroff, PhD, Chief, Behavioral Sciences Service, Memorial Sloan Kettering Cancer Center
- Ray U. Osarogiagbon, MBBS, FACP, Chief Scientist; Director, Baptist Memorial Healthcare Corporation; Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center
- Alison Mayer Sachs, MSW, LSW, CSW, OSW-C, FAOSW , Director, Community Outreach & Cancer Support Services, Eisenhower Lucy Curci Cancer Center
Quality of Life Committee
- Pamela Samson, MD, MPHS, Assistant Professor, Department of Radiation Oncology, Washington University in Saint Louis
- Jamie L. Studts, PhD, Professor, Division of Medical Oncology; Scientific Director, Behavioral Oncology, University of Colorado School of Medicine
- Kerri B. Susko, LISW-CP, OSW-C, Counselor, Center for Integrative Oncology and Survivorship & Director, Cancer Support Community, Prisma Health Cancer
- Jennifer Temel, MD, Professor of Medicine, Harvard Medical School; Director, Cancer Outcomes Research and Education Program, Massachusetts General Hospital
.